WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206045
CAS#: 266359-83-5 (free base)
Description: Reparixin is an inhibitor of CXCR2 function, which attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. In a human breast cancer cell line, both reparixin reduced the number of breast cancer stem cells compared with no treatment. I n mice with primary human breast cancer xenografts, reparixin alone or in combination with docetaxel reduced tumor growth compared with saline control. The combination had greater efficacy than either reparixin or docetaxel alone.
MedKoo Cat#: 206045
CAS#: 266359-83-5 (free base)
Chemical Formula: C14H21NO3S
Exact Mass: 283.12421
Molecular Weight: 283.39
Elemental Analysis: C, 59.34; H, 7.47; N, 4.94; O, 16.94; S, 11.31
Reparixin is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Related CAS #: 266359-83-5 (free) 266359-93-7 (lysine salt)
Synonym: DF 1681Y; DF-1681Y; DF1681Y; Reparixin; Repertaxin.
IUPAC/Chemical Name: (R)-2-(4-isobutylphenyl)-N-(methylsulfonyl)propanamide
InChi Key: KQDRVXQXKZXMHP-LLVKDONJSA-N
InChi Code: InChI=1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)/t11-/m1/s1
SMILES Code: C[C@H](C1=CC=C(CC(C)C)C=C1)C(NS(=O)(C)=O)=O
The following data is based on the product molecular weight 283.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Kim HY, Choi JH, Kang YJ, Park SY, Choi HC, Kim HS. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(1):120-7. PubMed PMID: 21212529.
2: Zarbock A, Allegretti M, Ley K. Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice. Br J Pharmacol. 2008 Oct;155(3):357-64. doi: 10.1038/bjp.2008.270. Epub 2008 Jun 30. PubMed PMID: 18587419; PubMed Central PMCID: PMC2567887.
3: Gorio A, Madaschi L, Zadra G, Marfia G, Cavalieri B, Bertini R, Di Giulio AM. Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. J Pharmacol Exp Ther. 2007 Sep;322(3):973-81. Epub 2007 Jun 29. PubMed PMID: 17601981.
4: Villa P, Triulzi S, Cavalieri B, Di Bitondo R, Bertini R, Barbera S, Bigini P, Mennini T, Gelosa P, Tremoli E, Sironi L, Ghezzi P. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med. 2007 Mar-Apr;13(3-4):125-33. PubMed PMID: 17592546; PubMed Central PMCID: PMC1892761.
5: Leitner JM, Mayr FB, Firbas C, Spiel AO, Steinlechner B, Novellini R, Jilma B. Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):25-36. PubMed PMID: 17346425.
6: Midgley I, Fitzpatrick K, Wright SJ, John BA, Peard AJ, Major RM, Holding JD, McBurney A, Anacardio R, Novellini R, Ferrari MP. Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog. Xenobiotica. 2006 May;36(5):419-40. PubMed PMID: 16854780.